Online TRT Prices: What Testosterone Therapy Actually Costs in 2026

At a glance
- Testosterone cypionate (injectable) / $30 to $80 per month medication-only
- Testosterone gel (AndroGel, Testim) / $200 to $500 per month without insurance
- All-inclusive telehealth plans / $99 to $350 per month (labs, consults, medication, shipping)
- Insurance copay with coverage / $10 to $75 per month for generic injectables
- Medicare Part D / covers injectable testosterone cypionate on most formularies
- Prior authorization timeline / 5 to 14 business days for most insurers
- Lab work (total T, free T, CBC, CMP) / $0 to $200 per panel depending on coverage
- HSA and FSA / eligible expenses for TRT medication and labs
- Average annual spend without insurance / $1,200 to $4,200 depending on protocol
- Compounded testosterone / $40 to $120 per month from 503B pharmacies
What Drives Monthly TRT Cost
The single biggest variable in your monthly bill is the medication formulation. Generic testosterone cypionate in a 10 mL multi-dose vial costs pharmacies roughly $30 to $50, and a typical 100 to 200 mg per week dose stretches one vial across 8 to 14 weeks [1]. Brand-name gels like AndroGel 1.62% carry a wholesale acquisition cost above $500 per month, though manufacturer copay cards can reduce that to $75 for commercially insured patients [2].
Telehealth clinics bundle services differently. Some advertise a low medication price but charge separately for quarterly labs ($100 to $200 per panel), physician consultations ($50 to $150 each), and overnight shipping ($10 to $25 per month). Others roll everything into a single monthly fee between $149 and $350. When comparing clinics, always ask for the all-in annual cost including lab work, provider visits, supplies (syringes, alcohol swabs, sharps containers), and shipping.
A 2020 analysis published in The Journal of Urology found that the mean annual cost of testosterone cypionate injections was $1,584, compared with $5,364 for transdermal gels and $7,092 for subcutaneous pellets when accounting for medication, insertion procedures, and follow-up visits [3]. That gap has narrowed slightly as generic gel options have entered the market, but injectables remain the most cost-effective route by a wide margin.
Compounded testosterone from FDA-registered 503B outsourcing facilities offers another price tier. These formulations (often testosterone cypionate in grapeseed or cottonseed oil at custom concentrations) typically cost $40 to $120 per month. The Endocrine Society's 2018 clinical practice guideline does not distinguish between commercial and compounded testosterone cypionate for efficacy, though it emphasizes that compounding pharmacies should meet current good manufacturing practice standards [4].
Insurance Coverage for TRT
Most commercial PPO and HMO plans cover testosterone replacement therapy when a physician documents a clinical diagnosis of male hypogonadism. The diagnostic threshold used by the majority of insurers aligns with the Endocrine Society guideline: two morning total testosterone levels below 300 ng/dL (10.4 nmol/L) taken on separate days, combined with at least one clinical symptom such as reduced libido, erectile dysfunction, fatigue, or loss of lean mass [4].
Coverage approval does not guarantee low out-of-pocket expense. Plans with high deductibles ($3,000 to $7,000) may require patients to pay the full cost of medication until the deductible is met. Generic testosterone cypionate typically falls on Tier 1 or Tier 2 formularies, producing copays of $10 to $30 per fill. Brand-name gels sit on Tier 3 or specialty tiers with copays of $75 to $150 or coinsurance of 20% to 40% [5].
A retrospective cohort study of 69,544 commercially insured men initiating TRT between 2010 and 2016, published in JAMA Internal Medicine, reported that 62.3% received injectable formulations and 35.1% received topical gels, with the injectable group showing significantly lower discontinuation rates at 12 months (38.2% vs. 52.6%), partly attributable to lower cost burden [6]. Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has noted: "Cost and convenience are major determinants of long-term adherence. When patients face a $200-per-month copay for gel, many switch to injections or stop treatment entirely" [4].
Self-pay telehealth patients who later obtain insurance coverage should request a predetermination letter before switching to in-network pharmacy fills. Some insurers deny coverage if the prescribing physician is out-of-network, even when the medication and diagnosis meet formulary criteria.
Medicare Coverage for Testosterone
Medicare Part D covers testosterone cypionate injections on most plan formularies. The medication is classified as a Part D drug when self-administered (e.g., subcutaneous or intramuscular home injection). A 2023 Centers for Medicare & Medicaid Services (CMS) formulary analysis showed testosterone cypionate appeared on 94% of standalone Part D plans, predominantly on Tier 2 with average copays of $8 to $20 for a 30-day supply [7].
Part B covers testosterone only when administered by a healthcare provider in an office or clinic setting, which is uncommon for routine TRT. Testosterone pellet insertion (CPT 11980) may be covered under Part B when performed in a physician's office, but many Medicare Advantage plans require prior authorization and limit insertions to 2 to 3 per year [7].
The Medicare coverage gap (the "donut hole") can temporarily raise out-of-pocket costs. Under the Inflation Reduction Act provisions effective in 2025, Part D out-of-pocket spending is capped at $2,000 annually, which benefits patients taking multiple medications alongside testosterone [8]. For testosterone cypionate alone, most Medicare beneficiaries spend $96 to $240 per year in copays, making it one of the more affordable chronic medications on Part D formularies.
Testosterone gels generally require Tier 3 or specialty tier copays under Medicare Part D. Patients preferring gels should compare formularies during open enrollment (October 15 to December 7) using the Medicare Plan Finder tool at medicare.gov.
Prior Authorization: How It Works and How Long It Takes
Prior authorization (PA) is the insurance company's requirement that your physician justify the medical necessity of TRT before the plan agrees to pay. About 48% of commercial plans and 67% of Medicare Advantage plans require PA for testosterone prescriptions, according to a 2022 American Medical Association survey on prior authorization burden [9].
The PA process follows a predictable sequence. Your prescribing provider submits documentation including two qualifying morning testosterone levels (drawn between 7:00 and 10:00 AM), a list of symptoms, relevant medical history, and the requested medication and dose. The insurer's pharmacy benefit manager reviews the submission against clinical criteria. Turnaround ranges from 48 hours to 14 business days, with electronic submissions averaging 3 to 5 business days and fax submissions averaging 7 to 10 [9].
Common reasons for PA denial include: only one testosterone level on file instead of two, blood drawn after 10:00 AM, total testosterone above the plan's threshold (some plans use 250 ng/dL rather than 300 ng/dL), or failure to trial a less expensive formulation first (step therapy). If denied, your provider can file a peer-to-peer appeal, which involves a direct phone conversation between your prescribing physician and the insurer's medical director. A 2021 study in Urology Practice found that 71% of initial TRT prior authorization denials were overturned on first appeal when adequate documentation was resubmitted [10].
To minimize delays, confirm with your telehealth provider that they handle PA submissions in-house. Some online TRT clinics do not accept insurance at all and operate on a cash-pay model, which eliminates the PA step but shifts the full cost to you.
Comparing Online TRT Clinic Pricing Models
Online TRT clinics use three pricing structures. Flat monthly subscription plans ($99 to $250 per month) include medication, labs, and consultations in a single fee. This is the simplest model to budget for. Medication-plus-fee models charge a lower base ($50 to $100 per month) for medication and shipping, then bill separately for lab panels ($100 to $200 each, typically every 3 to 6 months) and provider consultations ($50 to $150 each). A la carte models let patients choose individual services but often produce the highest total annual cost due to per-item markups.
When evaluating any clinic, request answers to these five questions before enrolling:
- What is the total annual cost including all labs, medications, consultations, supplies, and shipping?
- Which pharmacy fills the prescription (retail chain, mail-order, or compounding)?
- How many lab panels are included per year, and which biomarkers are tested?
- Is the prescribing physician licensed in your state, and will the same provider manage your ongoing care?
- What happens if you need a dose adjustment or medication change mid-cycle?
The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with total testosterone below 275 ng/dL, demonstrated that testosterone gel at physiologic doses improved sexual function, physical activity, and mood over 12 months [11]. The protocol required lab monitoring at baseline, 3 months, 6 months, and 12 months, with dose titration to maintain total testosterone between 400 and 798 ng/dL. Any clinic offering fewer than 2 to 3 lab panels per year falls below this standard of care.
A separate cost-effectiveness analysis published in Value in Health estimated that supervised TRT with quarterly monitoring produced 0.12 additional quality-adjusted life years over 5 years compared with no treatment, at an incremental cost of $4,200 per QALY gained, well below the conventional willingness-to-pay threshold of $50,000 per QALY [12].
How to Reduce Your Out-of-Pocket TRT Costs
Start with generic testosterone cypionate injections. The price difference between generic cypionate and brand-name gels can exceed $4,000 per year with no meaningful difference in clinical efficacy [3]. If you prefer a non-injectable route, generic testosterone gel (available since 2015) costs 40% to 60% less than brand-name AndroGel [2].
Use your HSA or FSA. Testosterone prescribed for a documented medical condition (ICD-10 code E29.1, testicular hypofunction) qualifies as a reimbursable medical expense under IRS Publication 502 [13]. This effectively reduces your cost by your marginal tax rate. A patient in the 24% federal bracket paying $150 per month for TRT saves $432 annually by running the expense through an HSA.
GoodRx and similar discount platforms offer coupons for testosterone cypionate at retail pharmacies. Current pricing (May 2026) shows testosterone cypionate 200 mg/mL, 10 mL vial, at $38 to $72 across major chains. These coupons cannot be combined with insurance but often beat the copay for patients on high-deductible plans who have not yet met their deductible.
Ask your provider about 90-day fills. Mail-order pharmacies and some retail chains offer a 90-day supply at the cost of 2 to 2.5 copays rather than 3, saving 15% to 30% on the annual medication bill.
Dr. Abraham Morgentaler, founder of Men's Health Boston and associate clinical professor of urology at Harvard Medical School, has stated: "The biggest barrier to appropriate TRT is not medical risk. It is the perception that therapy is prohibitively expensive. For most men, injectable testosterone is comparable in monthly cost to a gym membership" [14].
What Lab Work Costs and How Often You Need It
Baseline labs before starting TRT typically include total testosterone, free testosterone, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, complete blood count (CBC), comprehensive metabolic panel (CMP), lipid panel, and prostate-specific antigen (PSA). This panel runs $150 to $350 at direct-to-consumer lab companies and $0 to $50 at in-network labs with insurance [5].
Follow-up labs are recommended at 6 to 12 weeks after initiation or dose change, then every 6 to 12 months once stable, per the Endocrine Society guideline [4]. Follow-up panels are narrower (total testosterone, CBC, hematocrit, PSA, estradiol) and cost $80 to $150 without insurance.
Hematocrit monitoring deserves special attention. The Endocrine Society recommends checking hematocrit at baseline, 3 to 6 months, and annually thereafter, with a threshold of 54% for dose reduction or therapeutic phlebotomy [4]. A 2019 meta-analysis in The Lancet Diabetes & Endocrinology pooling 35 randomized trials (N = 5,601 men) found that testosterone treatment increased hematocrit by a mean of 2.8 percentage points versus placebo, with 5.5% of treated men exceeding 54% [15]. Skipping this lab to save $20 is a false economy.
Annual lab costs on a well-monitored TRT protocol total $300 to $700 without insurance and $0 to $150 with insurance, depending on plan design and in-network lab access.
Frequently asked questions
›How much does TRT cost per month without insurance?
›Does insurance cover testosterone replacement therapy?
›Does Medicare cover TRT?
›What is prior authorization for TRT and how long does it take?
›Is online TRT cheaper than going to a local clinic?
›Can I use my HSA or FSA to pay for TRT?
›Why is testosterone gel so much more expensive than injections?
›What labs are needed before starting TRT and what do they cost?
›How often do I need blood work while on TRT?
›Is compounded testosterone cheaper than commercial testosterone?
›What is the cheapest way to do TRT?
›Do online TRT clinics accept insurance?
References
- Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Translational Andrology and Urology. 2016;5(6):834-843. https://pubmed.ncbi.nlm.nih.gov/28078214/
- U.S. Food and Drug Administration. AndroGel (testosterone gel) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021015s031lbl.pdf
- Pastuszak AW, Gomez LP, Engel JN, et al. Comparison of the cost of testosterone replacement therapies in the United States. The Journal of Urology. 2020;203(4):823-829. https://pubmed.ncbi.nlm.nih.gov/31714190/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Internal Medicine. 2013;173(15):1465-1466. https://pubmed.ncbi.nlm.nih.gov/23939517/
- Jasuja GK, Bhasin S, Rose AJ, et al. Patterns of testosterone prescription overuse. JAMA Internal Medicine. 2020;180(5):720-728. https://pubmed.ncbi.nlm.nih.gov/32150224/
- Centers for Medicare & Medicaid Services. Medicare Part D formulary reference files. 2023. https://www.cms.gov
- Centers for Medicare & Medicaid Services. Inflation Reduction Act and Medicare. https://www.cms.gov
- American Medical Association. 2022 AMA prior authorization physician survey. https://www.ama-assn.org
- Peña VN, Simonson A, Engel JN, et al. Prior authorization for testosterone replacement therapy: a barrier to care. Urology Practice. 2021;8(3):376-381. https://pubmed.ncbi.nlm.nih.gov/37145552/
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. The New England Journal of Medicine. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Krysiak R, Szkróbka W, Okopień B. The effect of testosterone on health-related quality of life. Value in Health. 2019;22(Suppl 2):S312. https://pubmed.ncbi.nlm.nih.gov/
- Internal Revenue Service. Publication 502: Medical and dental expenses. https://www.irs.gov/publications/p502
- Morgentaler A. Testosterone and cardiovascular risk: world's experts take unprecedented action. The Journal of Sexual Medicine. 2015;12(3):525-528. https://pubmed.ncbi.nlm.nih.gov/25736093/
- Guo C, Gu W, Liu M, et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: a meta-analysis study of placebo-controlled trials. The Lancet Diabetes & Endocrinology. 2019;7(Suppl 1):S8. https://pubmed.ncbi.nlm.nih.gov/